Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Kumar Neil, holds the title of Chief Executive Officer at BridgeBio Pharma, Inc..
On 2026-11-16, the insider transacted 107,452 shares.The shares were transacted at a weighted average price of $26.09 per share, resulting in a total market-relevant value of $2.8M.
Kumar Neil (Chief Executive Officer) had withheld for taxes $2.8M of $BBIO
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.